Wave Life Sciences Ltd. (NASDAQ: WVE) has successfully priced an upsized $200 million public offering of its ordinary shares and pre-funded warrants. The offering includes 23,125,001 ordinary shares priced at $8.00 per share and pre-funded warrants to purchase up to 1,875,023 ordinary shares at an offering price of $7.9999 per pre-funded warrant. The gross proceeds expected from the offering are approximately $200 million.
The company also granted the underwriters a 30-day option to purchase up to an additional 3,750,000 of its ordinary shares on the same terms and conditions. The offering is expected to close on or about September 27, 2024, subject to customary closing conditions.
J.P. Morgan and Leerink Partners are acting as joint book-running managers for the offering, while Truist Securities and Mizuho are acting as book-runners.
This press release does not constitute an offer to sell, or a solicitation of an offer to buy, nor will there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
Wave Life Sciences is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. The company's diversified pipeline includes clinical programs in Duchenne muscular dystrophy, alpha-1 antitrypsin deficiency, and Huntington's disease, as well as a preclinical program in obesity. Wave is headquartered in Cambridge, MA. Today the company's shares have moved 3.1% to a price of $8.27. For more information, read the company's full 8-K submission here.
